These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34288506)

  • 1. Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer.
    Uematsu T; Torimoto K; Tanaka N; Asakawa I; Hori S; Yamaki K; Nakai Y; Miyake M; Anai S; Hasegawa M; Fujimoto K
    Low Urin Tract Symptoms; 2022 Jan; 14(1):4-9. PubMed ID: 34288506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy.
    Iinuma K; Nakano M; Kato T; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Ishihara T; Ito M; Matsuo M; Koie T
    Urology; 2020 Aug; 142():213-220. PubMed ID: 32416115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
    Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of lower urinary tract symptoms following seed implant for prostate cancer].
    Okaneya T; Nishizawa S; Iijima K; Yamagishi T; Kamigaito T; Hashida I; Hosaka N
    Hinyokika Kiyo; 2012 Apr; 58(4):185-91. PubMed ID: 22684258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.
    Miyake M; Tanaka N; Asakawa I; Yamaki K; Inoue T; Suzuki S; Hori S; Nakai Y; Anai S; Torimoto K; Toritsuka M; Nakagawa H; Tsukamoto S; Fujii T; Ohbayashi C; Hasegawa M; Kasahara M; Fujimoto K
    Contemp Clin Trials Commun; 2020 Sep; 19():100593. PubMed ID: 32637724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
    Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
    Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
    Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
    Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
    Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system.
    Taniguchi T; Iinuma K; Nakano M; Kawase M; Takeuchi S; Kato D; Takai M; Nakane K; Ishihara T; Ito M; Kumano T; Matsuo M; Koie T
    Prostate Int; 2022 Dec; 10(4):207-212. PubMed ID: 36570644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
    Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
    Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing long-term urinary symptoms after prostate brachytherapy.
    Stone NN; Winoker JS; Kaplan SA; Stock RG
    BJU Int; 2018 Nov; 122(5):831-836. PubMed ID: 29726091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.
    Yu YD; Kang MH; Choi CI; Shin HS; Oh JJ; Park DS
    World J Urol; 2016 Sep; 34(9):1269-74. PubMed ID: 26868648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?
    Steggerda MJ; Witteveen T; van den Boom F; Moonen LM
    Radiother Oncol; 2013 Nov; 109(2):251-5. PubMed ID: 24060176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.